World Journal of Nuclear Medicine

: 2013  |  Volume : 12  |  Issue : 3  |  Page : 81-

Honour the Scientist

John Richard Buscombe 
 Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge CB2 0QQ, United Kingdom

Correspondence Address:
John Richard Buscombe
Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge CB2 0QQ
United Kingdom

How to cite this article:
Buscombe JR. Honour the Scientist.World J Nucl Med 2013;12:81-81

How to cite this URL:
Buscombe JR. Honour the Scientist. World J Nucl Med [serial online] 2013 [cited 2022 Jan 28 ];12:81-81
Available from:

Full Text

As the recent death of Prof. Ajit Padhy begins to sink in we have all been thinking of different ways in which we can honour his memory. It is hard to think of someone who has not influenced the nuclear medicine community world-wide in the last 2 decades.

Many will remember Ajit the friend, the teacher, the organiser but we must also remember Ajit the scientist. At the heart of what he achieved over the past 30 years has been a commitment to science.

With his colleagues at the All India Institute of Medical Sciences he performed a prospective trial showing that post thyroidectomy ablation could be achieved with much lower activities of I-131 than previously though [1] -a concept which is now rapidly gaining ground in the developing world.

Ajit was always concerned that all should have access to radionuclide therapy and at his time in the IAEA he set up a funded project to develop and trial 188 Re-lipiodol for hepatocellular cancer. [2]

These are but 2 examples of his work. He has a great influence on scientific researchers across the world. As a consequence the editors of the World Journal of Nuclear Medicine would like to collate a special issue of the journal where those of you who have unpublished scientific work linked to Ajit's work or inspired by Ajit present their work. We would like all such papers submitted by July 1 st 2014 for a special issue to be published later that year. To ensure inclusion in the special edition please ensure that this is noted in the paper itself or in a covering letter/E-mail.

Let us all honour Ajit the scientist.


1Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996;77:2574-80.
2Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, et al. Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: Results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys 2007;69:1448-55.